Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, discusses the different circumstances in the level of restrictions and evidence regarding comparative effectiveness research. In addition, Dr. Dubois asks whether the standards around safety differ from those around efficacy.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More